Pharma-Bio Serv (PBSV) Revenue (2010 - 2026)

Pharma-Bio Serv (PBSV) has reported Revenue for 16 consecutive years, with $2.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Revenue rose 11.83% year-over-year to $2.7 million; the trailing twelve-month figure through Apr 2026 stood at $9.1 million (down 5.49% YoY), and the FY2025 full-year result was $9.0 million, down 5.34% from the prior year.
• Revenue grew to $2.7 million in Q2 2026 per PBSV's latest filing, from $2.3 million in the prior quarter.
• Across five years, Revenue topped out at $5.0 million in Q1 2022 and bottomed at $2.0 million in Q3 2025.
• Historically, Revenue has averaged $3.3 million across 5 years, with a median of $2.6 million in 2025.
• The sharpest annual moves came in 2024 and 2026: Revenue tumbled 47.9% in 2024, then grew 11.83% in 2026.
• Over 5 years, Revenue stood at $4.6 million in 2022, then declined by 22.42% to $3.6 million in 2023, then slumped by 35.15% to $2.3 million in 2024, then retreated by 7.87% to $2.1 million in 2025, then advanced by 25.74% to $2.7 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $2.7 million, $2.3 million, and $2.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.